YK-11

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
YK-11
Clinical data
Other namesMyostine; YK-11; 17α-methyl-δ2-17β-hydroxyestra-4,9-dien-3-one
Identifiers
  • Methyl (2E)-2-[(8R,9S,10R,13S,14S,17S)-2'-methoxy-2',13-dimethyl-3-oxospiro[1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-17,5'-1,3-dioxolane]-4'-ylidene]acetate
CAS Number
PubChem CID
ChemSpider
UNII
E number{{#property:P628}}
CompTox Dashboard (EPA)
  • {{#property:P3117}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC25H34O6
Molar mass430.541 g·mol−1
3D model (JSmol)
  • C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@]24/C(=C\C(=O)OC)/OC(O4)(C)OC)CCC5=CC(=O)CC[C@H]35
  • InChI=1S/C25H34O6/c1-23-11-9-18-17-8-6-16(26)13-15(17)5-7-19(18)20(23)10-12-25(23)21(14-22(27)28-3)30-24(2,29-4)31-25/h13-14,17-20H,5-12H2,1-4H3/b21-14+/t17-,18+,19+,20-,23-,24?,25+/m0/s1
  • Key:KCQHQCDHFVGNMK-PQUNLUOYSA-N

YK-11 is a synthetic, steroidal selective androgen receptor modulator (SARM) structurally derived from dihydrotestosterone (DHT). It is currently classified as an experimental compound and has not been approved for medical use in humans. Despite this, it has been widely researched in preclinical settings for its potent anabolic effects on muscle cells.

Overview

[edit | edit source]

YK-11 is distinct among SARMs due to its steroidal structure, setting it apart from most non-steroidal SARMs like Ostarine or LGD-4033. It binds to the androgen receptor (AR), similar to anabolic steroids, but its downstream activity differs significantly.

Mechanism of action

[edit | edit source]

YK-11 functions as a partial agonist of the androgen receptor. It activates the receptor but not to the full extent like natural androgens such as testosterone or DHT. It does not promote the typical N/C-terminal interaction within the AR, which is required for full transcriptional activation.[1]

Instead, YK-11 induces muscle growth through a secondary mechanism: it significantly increases the expression of follistatin, a potent inhibitor of myostatin—a protein that suppresses muscle growth.[2]

In vitro and animal studies

[edit | edit source]

Laboratory studies on mouse and human myoblasts (muscle precursor cells) have shown that:

  • YK-11 increases muscle cell differentiation and growth more potently than DHT.[2]
  • It exhibits strong anabolic activity without stimulating androgenic effects on non-muscle tissue (though this has only been evaluated in vitro so far).
  • In animal models, it has demonstrated protective effects against muscle wasting due to sepsis, suggesting potential therapeutic uses.[3]


See also

[edit | edit source]

References

[edit | edit source]
  1. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  2. ^ a b Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  3. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).